Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTX NYSE:CYBN NASDAQ:MDCX NASDAQ:NKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTXAvalo Therapeutics$10.14-4.8%$8.26$3.39▼$16.00$140.14M0.88159,656 shs187,343 shsCYBNCybin$6.01-1.3%$7.25$4.81▼$13.88$141.78M0.68352,224 shs574,296 shsMDCXMedicus Pharma$2.48+2.9%$2.43$1.79▼$8.94$42.94MN/A393,293 shs285,359 shsNKTXNkarta$1.97$2.09$1.31▼$5.88$139.92M0.76492,930 shs745,501 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTXAvalo Therapeutics0.00%-8.19%+18.07%+131.02%+18.60%CYBNCybin0.00%-9.51%-13.74%-24.25%+1,550.41%MDCXMedicus Pharma0.00%+28.19%+22.96%-9.40%+240,999,900.00%NKTXNkarta0.00%-12.83%-15.45%+4.23%-65.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTXAvalo Therapeutics$10.14-4.8%$8.26$3.39▼$16.00$140.14M0.88159,656 shs187,343 shsCYBNCybin$6.01-1.3%$7.25$4.81▼$13.88$141.78M0.68352,224 shs574,296 shsMDCXMedicus Pharma$2.48+2.9%$2.43$1.79▼$8.94$42.94MN/A393,293 shs285,359 shsNKTXNkarta$1.97$2.09$1.31▼$5.88$139.92M0.76492,930 shs745,501 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTXAvalo Therapeutics0.00%-8.19%+18.07%+131.02%+18.60%CYBNCybin0.00%-9.51%-13.74%-24.25%+1,550.41%MDCXMedicus Pharma0.00%+28.19%+22.96%-9.40%+240,999,900.00%NKTXNkarta0.00%-12.83%-15.45%+4.23%-65.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTXAvalo Therapeutics 3.00Buy$30.00195.86% UpsideCYBNCybin 3.25Buy$85.001,314.31% UpsideMDCXMedicus Pharma 3.50Strong Buy$23.50847.58% UpsideNKTXNkarta 3.00Buy$13.60590.36% UpsideCurrent Analyst Ratings BreakdownLatest MDCX, AVTX, CYBN, and NKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/5/2025AVTXAvalo TherapeuticsCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy9/5/2025AVTXAvalo TherapeuticsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy9/2/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.008/22/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.008/15/2025AVTXAvalo TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight8/14/2025NKTXNkartaStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$14.00 ➝ $12.008/13/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.008/13/2025NKTXNkartaNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.007/9/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.007/8/2025CYBNCybinCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$73.00 ➝ $70.007/1/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTXAvalo Therapeutics$440K303.05N/AN/A$12.80 per share0.79CYBNCybinN/AN/AN/AN/A$10.83 per shareN/AMDCXMedicus PharmaN/AN/AN/AN/A$0.29 per shareN/ANKTXNkartaN/AN/AN/AN/A$5.78 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTXAvalo Therapeutics-$35.13MN/A0.00N/AN/AN/A-48.48%-35.94%11/6/2025 (Estimated)CYBNCybin-$57.88M-$4.60N/AN/AN/AN/A-37.58%-36.59%N/AMDCXMedicus Pharma-$11.16M-$1.34N/AN/AN/AN/A-549.30%-228.06%11/28/2025 (Estimated)NKTXNkarta-$108.79M-$1.48N/AN/AN/AN/A-27.74%-22.38%11/6/2025 (Estimated)Latest MDCX, AVTX, CYBN, and NKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025NKTXNkarta-$0.37-$0.31+$0.06-$0.31N/AN/A8/11/2025Q2 2025MDCXMedicus Pharma-$0.39-$0.43-$0.04-$0.43N/AN/A8/7/2025Q2 2025AVTXAvalo Therapeutics-$1.43-$1.92-$0.49-$1.92N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTXAvalo TherapeuticsN/AN/AN/AN/AN/ACYBNCybinN/AN/AN/AN/AN/AMDCXMedicus PharmaN/AN/AN/AN/AN/ANKTXNkartaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTXAvalo TherapeuticsN/A12.4412.44CYBNCybinN/A24.2424.24MDCXMedicus PharmaN/A1.291.29NKTXNkartaN/A15.6715.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTXAvalo Therapeutics87.06%CYBNCybin17.94%MDCXMedicus PharmaN/ANKTXNkarta80.54%Insider OwnershipCompanyInsider OwnershipAVTXAvalo Therapeutics0.25%CYBNCybin15.00%MDCXMedicus Pharma11.20%NKTXNkarta8.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTXAvalo Therapeutics4013.15 million13.12 millionNot OptionableCYBNCybin5023.59 million17.96 millionNot OptionableMDCXMedicus PharmaN/A17.82 million15.82 millionN/ANKTXNkarta14071.03 million65.06 millionOptionableMDCX, AVTX, CYBN, and NKTX HeadlinesRecent News About These CompaniesAlyeska Investment Group L.P. Grows Position in Nkarta, Inc. $NKTXSeptember 8, 2025 | marketbeat.comNuveen LLC Invests $258,000 in Nkarta, Inc. $NKTXSeptember 8, 2025 | marketbeat.comAWM Investment Company Inc. Increases Holdings in Nkarta, Inc. $NKTXSeptember 5, 2025 | marketbeat.comNkarta to Participate in a September Investor ConferenceSeptember 2, 2025 | globenewswire.comNkarta, Inc. (NASDAQ:NKTX) Given Average Recommendation of "Buy" by BrokeragesAugust 26, 2025 | marketbeat.comEquities Analysts Issue Forecasts for Nkarta Q3 EarningsAugust 17, 2025 | marketbeat.comEquities Analysts Set Expectations for Nkarta Q3 EarningsAugust 17, 2025 | marketbeat.comWall Street Zen Upgrades Nkarta (NASDAQ:NKTX) to "Hold"August 17, 2025 | marketbeat.comNkarta (NASDAQ:NKTX) Given New $12.00 Price Target at Stifel NicolausAugust 16, 2025 | marketbeat.comNkarta (NASDAQ:NKTX) Receives Buy Rating from Needham & Company LLCAugust 15, 2025 | marketbeat.comNkarta price target lowered to $12 from $14 at StifelAugust 15, 2025 | msn.comNkarta, Inc.: Nkarta Reports Second Quarter 2025 Financial Results and Corporate HighlightsAugust 13, 2025 | finanznachrichten.deNkarta, Inc. Reports Q2 2025 Financial ResultsAugust 12, 2025 | tipranks.comNkarta Reports Second Quarter 2025 Financial Results and Corporate HighlightsAugust 12, 2025 | globenewswire.comNkarta to Participate in the H.C. Wainwright "HCW@Home" SeriesJuly 23, 2025 | tmcnet.comNkarta to Participate in the H.C. Wainwright “HCW@Home” SeriesJuly 23, 2025 | globenewswire.comNkarta: Holding Its Support Steady Ahead Of First Data Readouts In 2025July 22, 2025 | seekingalpha.comWill Nkarta (NASDAQ:NKTX) Spend Its Cash Wisely?June 27, 2025 | uk.finance.yahoo.comNkarta, Inc. (NKTX) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comNkarta CMO David Shook Steps Down, Shawn Rose To SucceedJune 7, 2025 | nasdaq.comNkarta, Inc.: Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune FocusJune 6, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMDCX, AVTX, CYBN, and NKTX Company DescriptionsAvalo Therapeutics NASDAQ:AVTX$10.14 -0.51 (-4.79%) Closing price 04:00 PM EasternExtended Trading$10.12 -0.02 (-0.15%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.Cybin NYSE:CYBN$6.01 -0.08 (-1.31%) Closing price 04:00 PM EasternExtended Trading$6.00 -0.01 (-0.15%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.Medicus Pharma NASDAQ:MDCX$2.48 +0.07 (+2.90%) As of 04:00 PM EasternMedicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.Nkarta NASDAQ:NKTX$1.97 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.96 0.00 (-0.25%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
